Cervical Cancer Susceptible Population Classification
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: PCR and sequence.
- Who it may be relevant to
- Registry conditions: Cervical Cancer Susceptible Population Classification. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evalutaion of the SNPs Test in Average Cervical Cancer Screening Episode
Overview
Cervical cancer is the third most common lethal tumor globally, causing around a quarter million deaths annually, despite the availability of HPV vaccines. Recent Genome-wide association studies (GWAS) have identified numerous genetic markers linked to cervical cancer, including rs10175462, rs10007915, rs35721900, and rs61646675, which have been verified as being related to susceptibility to cervical cancer. However, many reports lack clarity, consistency, and validation. In this comprehensive study, we will analyze the genomic risk factors associated with cervical cancer, classify individuals into different risk categories, and explore potential biomarkers and therapeutics.
Interventions
- Genetic PCR and sequence
sequence the mutatation SNPs
Primary outcome measures
- Evalutaiton of the SNPs test in an average cervical cancer patients screening episode [Time frame: two years]
Secondary outcome measures (1)
- Classified susceptied person into different ladders [Time frame: two years]
Eligibility criteria
Inclusion criteria
- Subjects aged >=18 years at time of consent
- Intended to undergo screening colposcopy
- Considered by a physician or healthcare provider as being of "average risk" for cervical cancer
- Willing to consent to blood draw cervical disease treatments
- Willing to sonsent to follow-up for five years as per protocol
Exclusion criteria
- History of cervical cancer
- History of any malignancy (patients who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study)
- Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs.
- Any major physical trauma (e.g. disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent
- Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- The First Affiliated Hospital of USTC — Hefei
Identifiers
NCT: NCT06405945 · Wila-Cer-01